PURPOSE: To define symptoms and therapeutic requirements for patients with metastatic or locally recurrent lung cancer. METHODS AND MATERIALS: Data were collected from 69 consecutive patients with locally advanced lung cancer seen in consultation at a radiation oncology facility serving a community hospital in Virginia. The Lung Cancer Symptom Scale, a validated quality of life instrument, measured the incidence of symptoms in this group. RESULTS: Average survival for the entire group was 7 months. Fifty-seven patients received 81 courses of radiation therapy, 33 directed at thoracic disease and 48 delivered to sites of metastasis. Thirty-three percent of those who received radiation therapy required treatment to more than one anatomic site. Every patient was symptomatic at the time of consultation, with the number (p = 0.001) and severity (p = 0.001) of symptoms they suffered worse in the patient group seen 0 to 3 months prior to death rather than 4 to 6 months prior to death. With the exception of cough, symptoms were marked in their severity. CONCLUSIONS: Patients with advanced lung cancer suffer frequent and severe symptoms that worsen in the final months of life. The appropriate timing and combination of radiotherapy and chemotherapy are yet to be resolved. Future studies will require use of validated quality of life instruments to better catalogue palliation and treatment toxicity.
PURPOSE: To define symptoms and therapeutic requirements for patients with metastatic or locally recurrent lung cancer. METHODS AND MATERIALS: Data were collected from 69 consecutive patients with locally advanced lung cancer seen in consultation at a radiation oncology facility serving a community hospital in Virginia. The Lung Cancer Symptom Scale, a validated quality of life instrument, measured the incidence of symptoms in this group. RESULTS: Average survival for the entire group was 7 months. Fifty-seven patients received 81 courses of radiation therapy, 33 directed at thoracic disease and 48 delivered to sites of metastasis. Thirty-three percent of those who received radiation therapy required treatment to more than one anatomic site. Every patient was symptomatic at the time of consultation, with the number (p = 0.001) and severity (p = 0.001) of symptoms they suffered worse in the patient group seen 0 to 3 months prior to death rather than 4 to 6 months prior to death. With the exception of cough, symptoms were marked in their severity. CONCLUSIONS:Patients with advanced lung cancer suffer frequent and severe symptoms that worsen in the final months of life. The appropriate timing and combination of radiotherapy and chemotherapy are yet to be resolved. Future studies will require use of validated quality of life instruments to better catalogue palliation and treatment toxicity.
Authors: Jan Gaertner; Rachel Wuerstlein; Ursula Klein; Dennis Scheicht; Sebastian Frechen; Jürgen Wolf; Martin Hellmich; Peter Mallmann; Nadia Harbeck; Raymond Voltz Journal: Breast Care (Basel) Date: 2011-06-14 Impact factor: 2.860
Authors: Susan Yount; Jennifer Beaumont; Sarah Rosenbloom; David Cella; Jyoti Patel; Thomas Hensing; Paul B Jacobsen; Karen Syrjala; Amy P Abernethy Journal: Clin Lung Cancer Date: 2011-05-23 Impact factor: 4.785
Authors: Charles B Simone; Joseph S Friedberg; Eli Glatstein; James P Stevenson; Daniel H Sterman; Stephen M Hahn; Keith A Cengel Journal: J Thorac Dis Date: 2012-02 Impact factor: 2.895
Authors: Kelly M Shaffer; Jamie M Jacobs; Ryan D Nipp; Alaina Carr; Vicki A Jackson; Elyse R Park; William F Pirl; Areej El-Jawahri; Emily R Gallagher; Joseph A Greer; Jennifer S Temel Journal: Support Care Cancer Date: 2016-11-19 Impact factor: 3.603
Authors: Jessica Fishman; Peter O'Dwyer; Hien L Lu; Hope R Henderson; Hope Henderson; David A Asch; David J Casarett Journal: Cancer Date: 2009-02-01 Impact factor: 6.860
Authors: Chris D Bailey; Richard Wagland; Rasha Dabbour; Ann Caress; Jaclyn Smith; Alex Molassiotis Journal: BMC Pulm Med Date: 2010-12-09 Impact factor: 3.317